ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "registry"

  • Abstract Number: 0496 • ACR Convergence 2024

    Dissecting Early RA Patient Trajectories Through Time-independent Disease State Identification Identifies Distinct Patterns Dissected by Inflammation in Blood or Joints

    Nils Steinz1, Tjardo Maarseveen2, Andrew Cope3, John Isaacs4, Aaron Winkler5, Thomas Huizinga6, Yann Abraham7 and Rachel Knevel1, 1Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Department of Rheumatology, Leiden University Medical Center, Wormerveer, Netherlands, 3King's College London, London, United Kingdom, 4Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, 5Pfizer Inc., Cambridge, MA, 6Department of Rheumatology, Leiden University, Leiden, Netherlands, 7Janssen Research and Development, Beerse, Belgium

    Background/Purpose: Patients with RA display different trajectories in the improvement of disease activity. Discerning the RA trajectories, how they differ between patients and which factors…
  • Abstract Number: 1377 • ACR Convergence 2024

    Evaluation of the Survival and Safety of Biologic and Targeted Synthetic DMARD in Patients with Difficult-to-Treat RA Using Real-World Data from a Nationwide Registry of Rheumatic Diseases

    Adrián Quevedo-Rodríguez1, Lucia Otero-Varela2, Fernando Sánchez-Alonso3, Yanira Pérez-Vera1, Javier Manero-Ruiz4, Cristina Campos-Fernández5, Sara Manrique-Arija6, Paloma Vela-Casasempere7, Antonio Mera-Varela8, César Díaz9, Atusa Movasat10, Blanca Garcia-Magallon11, Inmaculada Ros-Vilamajó12, Carolina Perez-Garcia13 and Isabel Castrejon14, and BIOBADASER working group., 1Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain, 2Spanish Society of Rheumatology, Madrid, Spain, 3Sociedad Española de Reumatología, Madrid, Spain, 4Hospital Universitario Miguel Servet, Zaragoza, Spain, 5Consorci Hospital General Universitari de València, Comunitat Valenciana, Spain, Valencia, Spain, 6Biomedical Research Institute of Malaga (IBIMA)-Bionand Platform, Department of Rheumatology, Regional University Hospital of Malaga, Malaga, Spain, 7Hospital General Universitario Alicante, Alicante, Spain, 8Department of Rheumatology. Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain, 9Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 10Hospital Universitario Príncipe de Asturias, Madrid, Spain, 11Hospital Universitario Puerta de Hierro Majadahonda., Madrid, Spain, 12Hospital Universitari Son Llàtzer, Palma de Mallorca, Islas Baleares, Spain, 13Hospital del Mar, Barcelona, Spain, 14Hospital General Universitario Gregorio Marañón and Complutense University of Madrid, Madrid, Spain

    Background/Purpose: Biologic and targeted synthetic disease-modifying drugs (b/tsDMARDs) have changed the way rheumatoid arthritis (RA) is managed in recent years. Still, some patients remain symptomatic…
  • Abstract Number: 2283 • ACR Convergence 2024

    Characterization of Second-Line Therapy After First Janus Kinase Inhibitor Use: Results from the CorEvitas RA Registry

    Joshua Baker1, Kristi Mizelle2, Wassim Saikali3, Page Moore4, Hyung-Joo Kang4, David Gruben5, Ahmed Shelbaya6, Lori Stockert7 and Jacqueline O'Brien4, 1Department of Medicine, Perelman School of Medicine University of Pennsylvania, Philadelphia, PA, 2TPMG Rheumatology, Newport News, VA, 3Rheumatology and Pulmonary Clinic, Beckley, WV, 4CorEvitas, LLC, Waltham, MA, 5Pfizer Inc, Groton, CT, 6Pfizer Inc, New York, NY, 7Pfizer Inc, Collegeville, PA

    Background/Purpose: Janus kinase inhibitors (JAKi) are a widely acceptable drug class in the treatment of RA. However, real-world data on the patterns of JAKi use and…
  • Abstract Number: 0501 • ACR Convergence 2024

    How Fast Do JAK-inhibitors, TNF-inhibitors, Abatacept and IL-6 Inhibitors Act in Rheumatoid Arthritis? An International Collaboration of Registers of Rheumatoid Arthritis Patients (the “JAK-pot” Study)

    Delphine Sophie Courvoisier1, Yacine Mrad1, Denis Mongin1, Romain Aymon2, Roberto Caporali3, Denis Choquette4, Catalin Codreanu5, Louis Coupal4, Doreen Huschek6, Kimme Hyrich7, Florenzo Iannone8, Tore K. Kvien9, Monika Mustak10, Dan Nordstrom11, Nina Trokovic12, Lucia Otero-Varela13, Karel Pavelka14, Manuel Enrique Pombo Suarez15, Sella A. Provan16, Ana Maria Rodrigues17, Ziga Rotar18, Prodromos Sidiropoulos19, Anja Strangfeld20, Jakub Závada14, Sizheng Zhao21, Axel Finckh1 and Kim Lauper1, 1Division of Rheumatology, Geneva University Hospitals, Geneva, Switzerland, 2Division of Rheumatology, Geneva University Hospitals, Collonges-sous-Salève, France, 3Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milan, Italy, 4Rhumadata™, Montreal, QC, Canada, 5University of Medicine and Pharmacy, Bucharest, Romania, 6German Rheumatism Research Center (DRFZ) Berlin, Berlin, Germany, 7Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom, 8Rheumatology Unit- University of Bari "Aldo Moro", IT, Bari, Italy, 9Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, 10Department of Internal Medicine II, Kaiser Franz Josef Hospital, Vienna, Austria, 11Helsinki University Hospital, Helsinki, Finland, 12Department of Medicine and Rheumatology ROB-FIN, Helsinki University Hospital, Helsinki, Finland, 13Spanish Society of Rheumatology, Madrid, Spain, 14Institute of Rheumatology and Charles University, Praha, Czech Republic, 15Rheumatology Department, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain, 16Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, 17Nova Medical School and Hospital dos Lusíadas, Lisbon, Portugal, 18University Medical Centre Ljubljana and University of Ljubljana, Ljubljana, Slovenia, 19University of Crete, Laboratory of Rheumatology, Autoimmunity and Inflammation. University Hospital, Rheumatology, Clinical Immunology. Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology, Heraklion, Greece, HERAKLIO, Greece, 20German Rheumatism Research Center (DRFZ) Berlin and Charité University Medicine, Berlin, Germany, 21Centre for Musculoskeletal Research, The University of Manchester, Liverpool, United Kingdom

    Background/Purpose: JAK-inhibitors (JAKi) have demonstrated a rapid onset of action; however, it is unclear how they compare to other targeted therapies in rheumatoid arthritis (RA).…
  • Abstract Number: 1404 • ACR Convergence 2024

    Modeling Diversity in Systemic Lupus Erythematosus (SLE) Clinical Trials Using Real-world Data (RWD) Sources

    Andrew Bevan1 and Nora Carroll2, 1Integrated Project Solutions, PPD, part of Thermo Fisher Scientific, Cambridge, United Kingdom, 2Cardiovascular and General Medicine, Thermo Fisher Scientific, Athlone, Ireland

    Background/Purpose: The FDA places emphasis on studying clinically relevant trial populations but does not address how these might be defined. SLE disproportionately affects women and…
  • Abstract Number: 2350 • ACR Convergence 2024

    Do Smoking and Obesity Impact Secukinumab Treatment Outcomes? Real-world Data from 1,202 European Patients with Psoriatic Arthritis

    Zohra Faizy Ahmadzay1, Stylianos Georgiadis2, Mikkel Ostergaard3, Bente Glintborg4, Signe Møller-Bisgaard5, Marion Pons6, Jette Heberg7, Sara Nysom Christiansen8, Simon Horskjær Rasmussen6, Anne Gitte Loft9, Isabel Castrejon10, Lucia Otero-Varela11, Jakub Závada12, Karel Pavelka12, Jarno Rutanen13, Laura Kuusalo14, Michael Nissen15, Ziga Rotar16, Katja Perdan-Pikmajer16, Miguel Bernardes17, Bjorn Gudbjornsson18, Gerdur Gröndal18, Irene E. van der Horst-Bruinsma19, Karin Laas20, Brigitte Michelsen21, Catalin Codreanu22, Daniela DiGuiseppe23, Burkhard Moeller24, Gökçe Kenar25, Merete Hetland26 and Lykke Oernbjerg2, 1Rigshospitalet Glostrup and Copenhagen University, Glostrup, Denmark, 2Rigshospitalet Glostrup, Glostrup, Hovedstaden, Denmark, 3Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark, 4DANBIO, Rigshospitalet Glostrup and University of Copenhagen, Virum, Denmark, 5Rigshospitalet, Glostrup and Slagelse Hospital, Glostrup, Denmark, 6Rigshospitalet Glostrup, Glostrup, Denmark, 7Rigshospitalet Glostrup, København V, Denmark, 8Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark., Glostrup, Denmark, 9Aarhus University Hospital and Aarhus University, Horsens, Denmark, 10Hospital General Universitario Gregorio Marañón and Complutense University of Madrid, Madrid, Spain, 11Spanish Society of Rheumatology, Madrid, Spain, 12Institute of Rheumatology and Charles University, Praha, Czech Republic, 13Tampere University Hospital, Tampere, Finland, 14University of Turku and Turku University Hospital, Turku, Finland, 15Geneva University Hospital, Geneva, Switzerland, 16University Medical Centre Ljubljana and University of Ljubljana, Ljubljana, Slovenia, 17São João Hospital Center and FMUP, Lisboa, Portugal, 18Landspitali University Hospital and University of Iceland, Reykjavik, Iceland, 19Department of Rheumatology, Radboud University Medical Centre, Nijmegen, Netherlands, 20East-Tallinn Central Hospital, Tallinn, Estonia, 21Rigshospitalet, Glostrup and Diakonhjemmet Hospital and Sørlandet Hospital, Kristiansand, Norway, 22University of Medicine and Pharmacy, Bucharest, Romania, 23Karolinska Institutet, Stockholm, 24Inselspital - University Hospital Bern, Bern, Switzerland, 25Dokuz Eylul University School of Medicine, Izmir, Turkey, 26Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark

    Background/Purpose: Smoking and obesity are common in patients with psoriatic arthritis (PsA) and can lead to higher disease activity and poorer response to treatment with…
  • Abstract Number: 0517 • ACR Convergence 2024

    Characterizing Infusion-Related Reactions in Patients with Rheumatoid Arthritis Treated with Biologic DMARDs: Observations from the KOBIO Registry

    Ji-Won Kim1, Ju-Yang Jung2, Chang-Hee Suh3 and Hyoun-Ah Kim1, 1Ajou university school of medicine, Suwon, South Korea, 2Ajou University of medical school, Suwon, South Korea, 3Ajou University Hospital, Suwon, South Korea

    Background/Purpose: The use of biologic disease-modifying antirheumatic drugs (bDMARDs) has revolutionized the management of rheumatoid arthritis (RA), despite their efficacy being occasionally limited by infusion-related…
  • Abstract Number: 1454 • ACR Convergence 2024

    Treatment Patterns, Clinical Characteristics, and Patient-Reported Outcomes Among Patients with Axial Spondyloarthritis Treated in Real-World Rheumatology Practices in the US

    Andrew Concoff1, Riley Taiji2, Linda Grennell-Merrick3, Jonathan Rodrigues3, Courtney McDermot4, Usha Madhukar Niak3, Raluca Ionescuittu5, Ariane Faucher2, Francis Vekeman2 and Tim Nguyen3, 1United Rheumatology, a Specialty Networks Company, Cleveland, OH, 2StatLog Econometrics, Montreal, QC, Canada, 3Novartis, East Hanover, NJ, 4Novartis, Dublin, Ireland, 5StatLog Economitrics, Montreal, QC, Canada

    Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic immune-mediated rheumatic disease with high comorbidity burden. Biologic disease-modifying anti-rheumatic drugs (bDMARDs) and patient-reported outcomes (PROs) are increasingly…
  • Abstract Number: 2365 • ACR Convergence 2024

    Benefits of Achieving Early versus Late Clinical Response After Treatment with Biologic and Targeted Synthetic DMARDs Among Patients with PsA in the CorEvitas PsA/Spondyloarthritis Registry

    Philip Mease1, Xiaolan Ye2, Christopher Saffore3, Thomas Iyile4, Priscila Magalhaes Reis Nakasato5, Taylor Blachley6, Paul R. Lakin6, Nicole Middaugh6 and Alexis Ogdie7, 1Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, 2AbbVie Inc., Mettawa, IL, 3AbbVie Inc., waukegan, IL, 4AbbVie Inc., hyattsville, MD, 5AbbVie Inc., Randolph, NJ, 6CorEvitas, LLC, Waltham, MA, 7Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Treatment for psoriatic arthritis (PsA) often involves biologic and targeted synthetic DMARDs (b/tsDMARDs). Existing research suggests that starting treatment with b/tsDMARDs early may lead…
  • Abstract Number: 0581 • ACR Convergence 2024

    Unmet Criteria for Achieving Minimal and Very Low Disease Activity Among Patients with Psoriatic Arthritis Initiating Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in the CorEvitas PsA/SpA Registry

    Alexis Ogdie1, Chao Song2, Nicole Middaugh3, Maya Marchese3, Melissa Eliot3, Robert Low2 and Philip Mease4, 1Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 2UCB Pharma, Smyrna, GA, 3CorEvitas, LLC, Waltham, MA, 4Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA

    Background/Purpose: Minimal disease activity (MDA) is associated with reduced radiographic progression and improved quality of life among patients (pts) with PsA.1 Clinical advances made MDA…
  • Abstract Number: 1460 • ACR Convergence 2024

    Safety and Effectiveness of 97 Combinations of Targeted Therapies in Immune Mediated Inflammatory Diseases : Preliminary Data from the COMBATT Registry

    Lou Kawka1, Jacques-Eric Gottenberg2, Jérôme Avouac3, OLIVIER BROCQ4, GILLES HAYEM5, Xavier Mariette6, Alain Meyer7, BENOIT FLACHAIRE8, OLIVIER FOGEL9, ARTHUR GANDIOLLE10, MANON LESTURGIE11, JEAN-FRANCOIS KLEINMANN12, Samira Ahmed Yahia13 and Thao Pham14, 1Hôpital Universitaire de Strasbourg, Strasbourg, Alsace, France, 2Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, 3Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, 4Service de Rhumatologie, centre hospitalier Princesse-Grâce, Monaco, Monaco, 5Groupe Hospitalier Paris Saint-Joseph, Paris, France, 6Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France, 7UR3072, Physiology Department, Rheumatology Department, University Hospital of Strasbourg, Strasbourg, France, 8Aix Marseille University, Marseille, France, 9AP-HP, Paris, France, 10Strasbourg University Hospital, Strasbourg, France, 11Cochin hospital, Paris, France, 12Rheumatology department strasbourg, Strasbourg, France, 13Hôpital Universitaire de Strasbourg, Strasbourg, France, 14Assistance Publique-Hôpitaux de Marseille, Marseille, France

    Background/Purpose: This study aimed to evaluate the clinical scenarios in which clinicians initiate cTT, as well as the safety and effectiveness of cTT in patients…
  • Abstract Number: 2412 • ACR Convergence 2024

    Validation of Proposals for Definitions of Moderate and Severe Disease Activity in Systemic Lupus Erythematosus, Based on Data Gathered from the RELESSER-PROS Register Database

    Irene Altabás-González1, Íñigo Rúa-Figueroa2, Coral Mouriño3, Ivonne Lourdes Mamani4, Karen Roberts5, Julia Martínez-Barrio6, María Galindo-Izquierdo7, Jaime Calvo-Alen8, MARIA CELIA ERAUSQUIN ARRUABARRENA9, Belen Serrano-Benavente6, Irene Carrión-Barberà10, Esther Uriarte-Isacelaya11, Eva Tomero Muriel12, Mercedes Freire González13, Ricardo Blanco-Alonso14, Eva Salgado-Pérez15, Paloma Vela-Casasempere16, Antonio Fernández-Nebro17, Alejandro Olive18, Clara Sanguesa19, Javier Narvaez-García20, Raúl Menor Almagro21, José Rosas-Gómez de Salazar22, José Ángel Hernández Beriain23, Francisco j. Manero-Ruiz24, Elena Aurrecoechea25, Carlos Montilla26, gema Bonilla27, Oihane Ibarguengoitia Barrena28, Vicenç Torrente-Segarra29, Ana Paula Cacheda30, María García-Villanueva31, Clara Moriano32, Loreto Horcada33, Nuria Lozano-rivas34, Cristina Bohorquez35 and José María Pego-Reigosa36, and RELESSER-Group, 1Complejo Hospitalario de Vigo, Vigo, Galicia, Spain, 2Department of Rheumatology, Hospital Universitario Doctor Negrín, Las Palmas de Gran Canaria, Las Palmas GC, Spain, 3Complejo Hospitalario Universitario de Vigo. IRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Galicia Sur Health Research Institute, Vigo, Spain, 4COMPLEJO HOSPITALARIO UNIVERSITARIO DE VIGO, Pontevedra, Spain, 5Sección Reumatología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 6Hospital Gregorio Marañón, Madrid, Spain, 7Hospital 12 de Octubre, Madrid, Madrid, Spain, 8Hospital Universitario de Araba, Araba, Spain, 9Gob Canarias, Tenerife, Canarias, Spain, 10Hospital del Mar, Barcelona, Spain, 11Hospital Univeritario de Donostia, San Sebastián, Spain, 12La Princesa Hospital, Madrid, Madrid, Spain, 13Complexo Hospitalario Universitario de A Coruña, La coruna, Galicia, Spain, 14Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain, 15Complejo Hospitalario de Orense, Ourense, Spain, 16Hospital General Universitario Alicante, Alicante, Spain, 17Department of Rheumatology, Hospital Universitario de Málaga, Málaga, Andalucia, Spain, 18Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain, 19Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 20Hospital Universitario de Bellvitge, Barcelona, Spain, 21Department of Rheumatology, Hospital Jerez de la Frontera, Jerez de la Frontera, Spain, 22Hospital Marina Baixa, PALMA DE MALLORCA, Comunidad Valenciana, Spain, 23Rheumatology Department. Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran C, Spain, 24H. Miguel Servet, Zaragoza, Spain, 25Hospital de Sierrallana, Torrelavega, Spain, 26Hospital Universitario de Salamanca, Salamanca, Castilla y Leon, Spain, 27Hospital Clínico Universitario La Paz, Madrid, Spain, 28Rheumatology Division, Galdakao-Usansolo University Hospital, Galdako, Spain, 29Hospital Comarcal Alt Penedès-Garraf, Vilafranca, Spain, 30Hospital Universitario Son Llàtzer, Mallorca, Spain, 31Hospital Ramón y Cajal, MADRID, Madrid, Spain, 32Hospital León, LEON, Spain, 33Hospital Complex of Navarra, Pamplona, Spain, 34Virgen de la Arrixaca University Hospital, Murcia, Spain, 35Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain, 36Galicia Health Service (SERGAS), Vigo, Spain

    Background/Purpose: In systemic lupus erythematosus (SLE), there is not a standardized and validated definition of states of moderate and severe SLE activity.  The aim of…
  • Abstract Number: 0582 • ACR Convergence 2024

    Achievement of Minimal and Very Low Disease Activity Among Patients with Psoriatic Arthritis Initiating Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in the CorEvitas PsA/SpA Registry

    Alexis Ogdie1, Chao Song2, Nicole Middaugh3, Maya Marchese3, Melissa Eliot3, Robert Low2 and Philip Mease4, 1Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 2UCB Pharma, Smyrna, GA, 3CorEvitas, LLC, Waltham, MA, 4Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA

    Background/Purpose: Minimal disease activity (MDA) is associated with clinically meaningful improvements in disease activity and patient (pt)-reported outcomes among pts with PsA.1 However, it is…
  • Abstract Number: 1671 • ACR Convergence 2024

    Are Patient-reported Outcomes for Dactylitis, Uveitis, Psoriatic Skin and Nail Disease Valid in Patients with Psoriatic Arthritis?

    Louise Nielung1, Merete Hetland2, Lone Skov3, Hans Albert Frandsen4, Lene Dreyer5 and Bente Glintborg6, 1Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark, 2DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark, Glostrup, Denmark, 3Department of Dermatology and Allergy, Copenhagen University Hospital - Herlev and Gentofte, Gentofte, Denmark, 4Patient Partner, Frederiksberg, Denmark, 5Department of Rheumatology, Aalborg UnIversity Hospital, København, Denmark, 6DANBIO, Rigshospitalet Glostrup and University of Copenhagen, Virum, Denmark

    Background/Purpose: In routine care, Danish patients with psoriatic arthritis (PsA) are monitored in DANBIO, a nationwide clinical registry1. Patients enter patient-reported outcomes (PROs) online before…
  • Abstract Number: 2618 • ACR Convergence 2024

    Population Health Management for Juvenile Idiopathic Arthritis in the Pediatric Rheumatology Care and Outcomes Improvement Network

    Julia Harris1, Catherine Bingham2, Sheetal Vora3, Cagri Yildirim-Toruner4, Kerry Ferraro5, Erik Friedrichsen6, Danielle Bullock7, Jon Burnham8, Tzielan Lee9, Daniel Lovell10, Ted Wimmel11, Delores Mincarelli11, Mayur Patil12, Magen Phillips11 and Esi Morgan13, 1Children's Mercy Kansas City, Overland Park, KS, 2Penn State Children’s Hospital, Hershey, 3Atrium Health Levine Children's Hospital, Charlotte, NC, 4Baylor College of Medicine/ Texas Children's Hospital, Houston, TX, 5JIA parent and CHOP volunteer, Lower Gwynedd, PA, 6Seattle Children's Hospital, Seattle, 7M Health Fairview Masonic Children’s Hospital, Minneapolis, 8Children's Hospital of Philadelphia, Philadelphia, PA, 9Stanford University School of Medicine, Palo Alto, CA, 10Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 11Hive Networks, Newport, 12VSquare Infotech Inc, Edison, NJ, 13Seattle Children's Hospital, Seattle, WA

    Background/Purpose: The Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) is a learning health network with a vision that children with rheumatic disease will have…
  • 1
  • 2
  • 3
  • …
  • 18
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology